Evidence map›Paper›PMID 41557023›Full record

ArticleClinical and experimental medicine2026

Comparative effectiveness and safety of vonoprazan/amoxicillin-based dual therapy versus quadruple therapy as second-line treatment for Helicobacter pylori Infection: a retrospective cohort study.

Ying-Ying Han, Ji-Yan Li, Ya-Ni Zhou, Lin Tuo, Ge Wang, Jing-Mei Liu, Zhen-Zhen Zhou, Mei Liu, Pei-Yuan Li

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Tetracycline for Helicobacter pylori eradication: a narrative review from quadruple to dual therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ying-Ying Han *Division of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Ji-Yan Li *Division of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Ya-Ni ZhouDivision of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Lin TuoDivision of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Ge WangDivision of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Jing-Mei LiuDivision of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Zhen-Zhen ZhouDivision of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Mei LiuDivision of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Pei-Yuan LiDivision of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China. pyli@tjh.tjmu.edu.cn.ORCID http://orcid.org/0000-0002-6300-1460

Funding

Hainan Province Science and Technology Special Fund ZDYF2022SHFZ057Natural Science Foundation of Hainan Province 823QN372Natural Science Foundation of Hubei Province 2023AFB347Tongji Hospital Clinical Research Fund 2024TJCR019
6 · The paper itself

Abstract

The introduction of vonoprazan has markedly enhanced the effectiveness of the first-line Helicobacter pylori (H. pylori) eradication regimens. This study aimed to compare the effectiveness of vonoprazan-amoxicillin based dual therapy with that of quadruple therapy as second-line treatments, while also investigating potential clinical predictors of therapeutic success. From January 2023 to June 2025, we retrospectively analyzed clinical data from H. pylori-infected patients who received second-line treatment with either: vonoprazan-amoxicillin dual therapy (VA) or VA based quadruple therapy (VAMB; vonoprazan, amoxicillin, minocycline, and colloidal bismuth pectin). The eradication status was evaluated by

Indexed as

AmoxicillinAnti-Bacterial AgentsHelicobacter InfectionsHelicobacter pyloriProton Pump InhibitorsPyrrolesSulfonamidesAdultAgedDrug Therapy, CombinationFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAmoxicillinAnti-Bacterial AgentsProton Pump InhibitorsPyrrolesSulfonamidesvonoprazanAmoxicillinBismuth quadruple therapyDual therapyHelicobacter pyloriSecond-line treatmentVonoprazan

Identifiers

PMID41557023
PMCPMC12847212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.